The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Maintenance interleukin-2 (IL-2) and sargramostim (GM-CSF) following high-dose IL-2 (HD IL-2) therapy for metastatic melanoma.
Melinda Bernabe Chu
No relevant relationships to disclose
Mark Fesler
No relevant relationships to disclose
Eric Armbrecht
No relevant relationships to disclose
Scott Fosko
No relevant relationships to disclose
Eddy C. Hsueh
No relevant relationships to disclose
John M. Richart
No relevant relationships to disclose